Pacific Drilling Announces Denial of Permission to Appeal Zonda Arbitration Decision
Pacific Drilling S.A. (NYSE: PACD) (the “Company”) announced today that the High Court in London has denied the application of the Company’s subsidiaries Pacific Drilling VIII Limited (“PDVIII”) and Pacific Drilling Services, Inc. (“PDSI”) for leave to appeal the previously-disclosed award that was issued in arbitration proceedings between PDVIII and PDSI and Samsung Heavy Industries Co. Ltd. (“SHI”) related to the contract for the construction and sale of the Pacific Zonda.
As previously disclosed, PDVIII and PDSI filed a separate plan of reorganization under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York, and that plan was confirmed on January 30, 2019. The Company expects that PDVIII and PDSI will proceed to be liquidated in accordance with the terms of their Chapter 11 plan.
About Pacific Drilling
With its best-in-class drillships and highly experienced team, Pacific Drilling is committed to exceeding our customers’ expectations by delivering the safest, most efficient and reliable deepwater drilling services in the industry. Pacific Drilling’s fleet of seven drillships represents one of the youngest and most technologically advanced fleets in the world. Pacific Drilling has principal offices in Luxembourg and Houston. For more information about Pacific Drilling, including our current Fleet Status, please visit our website at www.pacificdrilling.com.
Forward-Looking Statements
Certain statements and information contained in this press release constitute “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and are generally identifiable by their use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “our ability to,” “may,” “plan,” “potential,” “predict,” “project,” “projected,” “should,” “will,” “would”, or other similar words which are not generally historical in nature. The forward-looking statements speak only as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.
Our forward-looking statements express our current expectations or forecasts of possible future results or events, and include statements regarding potential timing and outcomes related to the Company’s potential legal remedies related to the Tribunal’s and High Court’s decisions, expectations regarding the Zonda Plan, and expectations regarding the impact of the Tribunal’s and High Court’s decisions on the Company’s operations, relationships, financial position, results of operations and liquidity.
Although we believe that the assumptions and expectations reflected in our forward-looking statements are reasonable and made in good faith, these statements are not guarantees, and actual future results may differ materially due to a variety of factors. These statements are subject to a number of risks and uncertainties and are based on a number of judgments and assumptions as of the date such statements are made about future events, many of which are beyond our control. Actual events and results may differ materially from those anticipated, estimated, projected or implied by us in such statements due to a variety of factors, including if one or more of these risks or uncertainties materialize, or if our underlying assumptions prove incorrect.
Important factors that could cause actual results to differ materially from our expectations include: the risks of litigation in foreign jurisdictions and delays caused by third parties in connection with such litigation, the outcome of the Zonda Plan, any actions that SHI or others may take in any proceedings against us and our subsidiaries, and the other risk factors described in our 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2020, as updated by our Quarterly Reports on Form 10-Q as filed with the SEC on May 9, 2020 and August 7, 2020 and subsequent filings with the SEC. These documents are available through our website at www.pacificdrilling.com or through the SEC’s website at www.sec.gov.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005702/en/
Contact information
Investor Contact:
James Harris
Pacific Drilling S.A.
+713 334 6662
Investor@pacificdrilling.com
Media Contact:
Amy L. Roddy
Pacific Drilling S.A.
+713 334 6662
Media@pacificdrilling.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Registry Data Show Meaningful Overall Survival Benefit in Patients with Advanced Cutaneous T-cell Lymphoma (CTCL) treated with POTELIGEO (mogamulizumab)22.10.2025 10:30:00 EEST | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and the University Hospitals Birmingham NHS Foundation Trust, today announced new overall survival (OS) insights from the PROCLIPI (PROgnostic Cutaneous Lymphoma International Prognostic Index) Study aligning with previous findings that suggest mogamulizumab may offer meaningful OS benefit for patients living with mycosis fungoides (MF) and Sézary syndrome (SS), two rare conditions and subtypes of cutaneous T-cell lymphoma (CTCL).2 Key findings2: For patients with advanced-stage MF and SS (n=371), the median overall survival from the onset of treatment was higher for patients treated with mogamulizumab (n=72) at 64 months compared with those not receiving mogamulizumab (n=175) at 54 months (p<0.01). Patients treated with mogamulizumab showed a trend toward improved OS compared to those not receiving mogamulizumab across risk
World First: H-UKR 0% Clinker Cement Obtains Technical Assessment (ATec) for Wind Turbine Foundations22.10.2025 09:00:00 EEST | Press release
Hoffmann Green Cement Technologies (ISIN: FR0013451044, Ticker: ALHGR) (“Hoffmann Green Cement” or the “Company”), an industrial player committed to the decarbonation of the construction sector that designs and markets innovative cold produced, clinker-free cements, today announces that it has obtained a Technical Assessment (ATec) validating the use of its H-UKR decarbonized cement for wind turbine foundations. This unprecedented recognition, a world first for a 0% clinker cement, certifies that the H-UKR solution meets the highest standards of sustainability, safety, and performance for particularly rigorous applications such as wind power. A strategic step towards new markets This certification marks another key milestone for Hoffmann Green, enabling it to further accelerate its growth in the renewable energy market from 2026 and beyond. Obtaining this ATec certification paves the way for new commercial opportunities in this sector, strengthening its insurability with project owners
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors22.10.2025 03:25:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into a license and collaboration agreement with Innovent Biologics (HKEX: 01801) for the development, manufacturing and commercialization of two late-stage oncology medicines, IBI363 and IBI343, worldwide outside of Greater China.* IBI363 is being evaluated in non-small cell lung and colorectal cancers and has shown potential efficacy in additional solid tumor types. IBI343 is being evaluated in gastric and pancreatic cancers. Takeda will also receive an exclusive option to license global rights outside of Greater China for IBI3001, an early-stage investigational medicine. “IBI363 and IBI343, two next-generation investigational medicines, have the potential to address critical treatment gaps for patients with a range of solid tumors,” said Teresa Bitetti, President, Global Oncology Business Unit, Takeda. “We are energized by the progress made by Innovent to date and look forward to collaborating to unlock the potential of t
YES Selected to Deliver Full Portfolio of Advanced Packaging Tools for Glass Panel AI and HPC Applications by a Leading AI Infrastructure Supplier21.10.2025 22:16:00 EEST | Press release
Yield Engineering Systems (YES), a leading provider of advanced process equipment for AI and high-performance computing (HPC) semiconductor applications, today announced that it has received multiple tool orders from a global leader in AI infrastructure solutions. The orders span YES’s portfolio of Dry and Wet process systems and will support panel-level manufacturing on glass substrates for next-generation data center and HPC packaging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020459437/en/ YES VertaCure, VertaPrime, VeroFlex, TersOra, and SURE systems. The systems will be deployed in advanced packaging lines dedicated to hyperscale AI workloads, including training, inference, networking, and co-packaged optics. This award marks a significant milestone in the industry's shift toward glass-based 2.5D and 3D packaging as system performance, density, and thermal requirements escalate. YES will supply a full suite of s
Esri and UNFPA Extend Strategic Partnership to Support 2030 Census Round21.10.2025 22:09:00 EEST | Press release
Esri, the global leader in location intelligence, today announced the extension of its strategic partnership with the United Nations Population Fund (UNFPA) in support of the 2030 census round. Building on a successful collaboration during the 2020 census round, the partnership aims to embed geographic information system (GIS) technology into all phases of census work. By leveraging GIS, national statistics and census offices will gain access to more authoritative, location-enabled data and faster, more efficient methods of planning, collection, and dissemination. “National census projects can often involve mapping an entire country,” said Linda Peters, Esri global business development manager. “GIS is becoming crucial for every step of a census but deploying it is new to many national statistical offices. We are happy to provide the resources that can enable this large-scale feat of authoritative data collection and communication.” The integration of location intelligence into census
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom